Perspective Therapeutics (CATX) Revenue & Revenue Breakdown
Perspective Therapeutics Revenue Highlights
Latest Revenue (Y)
$7.10M
Latest Revenue (Q)
$1.91M
Perspective Therapeutics Revenue by Period
Perspective Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2022-12-31 | $7.10M | -34.19% |
| 2022-06-30 | $10.79M | 7.38% |
| 2021-06-30 | $10.05M | 3.85% |
| 2020-06-30 | $9.68M | 32.35% |
| 2019-06-30 | $7.31M | 23.48% |
| 2018-06-30 | $5.92M | 24.41% |
| 2017-06-30 | $4.76M | -0.17% |
| 2016-06-30 | $4.77M | 3.53% |
| 2015-06-30 | $4.61M | 9.18% |
| 2014-06-30 | $4.22M | -6.76% |
| 2013-06-30 | $4.53M | -10.76% |
| 2012-06-30 | $5.07M | -3.20% |
| 2011-06-30 | $5.24M | -0.89% |
| 2010-06-30 | $5.29M | -2.43% |
| 2009-06-30 | $5.42M | -24.32% |
| 2008-06-30 | $7.16M | 24.76% |
| 2007-06-30 | $5.74M | 187.72% |
| 2006-06-30 | $1.99M | 100.00% |
| 2004-09-30 | - | 100.00% |
| 2003-09-30 | - | 100.00% |
| 2002-09-30 | - | 100.00% |
| 2001-09-30 | - | 100.00% |
| 2000-09-30 | - | 100.00% |
| 1999-09-30 | - | 100.00% |
| 1998-09-30 | - | -100.00% |
| 1997-09-30 | $7.85M | -4.96% |
| 1996-09-30 | $8.26M | 5.64% |
| 1995-09-30 | $7.82M | 15.16% |
| 1994-09-30 | $6.79M | - |
Perspective Therapeutics generated $7.10M in revenue during NA 2022, up -34.19% compared to the previous quarter, and up 119.94% compared to the same period a year ago.
Perspective Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-09-30 | $1.91M | 27.27% |
| 2023-06-30 | $1.50M | -18.03% |
| 2023-03-31 | $1.83M | -0.27% |
| 2022-12-31 | $1.83M | 6.87% |
| 2022-09-30 | $1.72M | -31.46% |
| 2022-06-30 | $2.50M | -13.92% |
| 2022-03-31 | $2.91M | 3.34% |
| 2021-12-31 | $2.82M | 9.83% |
| 2021-09-30 | $2.56M | -5.39% |
| 2021-06-30 | $2.71M | 4.23% |
| 2021-03-31 | $2.60M | 10.22% |
| 2020-12-31 | $2.36M | -1.05% |
| 2020-09-30 | $2.38M | 4.61% |
| 2020-06-30 | $2.28M | -20.87% |
| 2020-03-31 | $2.88M | 30.55% |
| 2019-12-31 | $2.21M | -4.71% |
| 2019-09-30 | $2.31M | 20.32% |
| 2019-06-30 | $1.92M | - |
| 2019-03-31 | $1.92M | 1.05% |
| 2018-12-31 | $1.90M | 21.90% |
| 2018-09-30 | $1.56M | -2.56% |
| 2018-06-30 | $1.60M | 1.91% |
| 2018-03-31 | $1.57M | 2.41% |
| 2017-12-31 | $1.54M | 26.84% |
| 2017-09-30 | $1.21M | -11.61% |
| 2017-06-30 | $1.37M | 6.86% |
| 2017-03-31 | $1.28M | 24.71% |
| 2016-12-31 | $1.03M | -4.90% |
| 2016-09-30 | $1.08M | -3.50% |
| 2016-06-30 | $1.12M | -6.55% |
| 2016-03-31 | $1.20M | 12.49% |
| 2014-12-31 | $1.07M | 2.25% |
| 2014-09-30 | $1.04M | 9.75% |
| 2014-06-30 | $949.52K | -16.29% |
| 2014-03-31 | $1.13M | 4.51% |
| 2013-12-31 | $1.09M | 3.38% |
| 2013-09-30 | $1.05M | -15.47% |
| 2013-06-30 | $1.24M | -0.75% |
| 2013-03-31 | $1.25M | 28.30% |
| 2012-12-31 | $975.46K | -7.65% |
| 2012-09-30 | $1.06M | -19.47% |
| 2012-06-30 | $1.31M | -0.43% |
| 2012-03-31 | $1.32M | 7.22% |
| 2011-12-31 | $1.23M | 1.26% |
| 2011-09-30 | $1.21M | -3.41% |
| 2011-06-30 | $1.26M | -10.95% |
| 2011-03-31 | $1.41M | 13.32% |
| 2010-12-31 | $1.24M | -6.19% |
| 2010-09-30 | $1.33M | -0.62% |
| 2010-06-30 | $1.34M | 10.99% |
| 2010-03-31 | $1.20M | -12.07% |
| 2009-12-31 | $1.37M | -0.78% |
| 2009-09-30 | $1.38M | 14.42% |
| 2009-06-30 | $1.21M | -11.79% |
| 2009-03-31 | $1.37M | 2.98% |
| 2008-12-31 | $1.33M | -12.69% |
| 2008-09-30 | $1.52M | - |
Perspective Therapeutics generated $1.91M in revenue during Q1 2023, up 27.27% compared to the previous quarter, and up 76.21% compared to the same period a year ago.
Perspective Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PAVM | PAVmed | $2.45B | $979.00M |
| LIVN | LivaNova | $1.15B | $318.60M |
| FNA | Paragon 28 | $216.39M | $61.02M |
| KIDS | OrthoPediatrics | $148.73M | $52.80M |
| SIBN | SI-BONE | $138.89M | $39.97M |
| SRDX | Surmodics | $132.58M | $30.34M |
| SGHT | Sight Sciences | $81.06M | $21.37M |
| LUNG | Pulmonx | $68.67M | $20.78M |
| NPCE | NeuroPace | $65.42M | $18.12M |
| CVRX | CVRx | $39.30M | $11.81M |
| OSA | ProSomnus | $27.65M | $7.46M |
| HYPR | Hyperfine | $11.03M | $3.63M |
| CATX | Perspective Therapeutics | $7.10M | $1.91M |
| OFIX | Orthofix Medical | $100.00K | $198.62M |
CATX Revenue FAQ
What is Perspective Therapeutics’s yearly revenue?
Perspective Therapeutics's yearly revenue for 2022 was $7.1M, representing a decrease of -34.19% compared to 2021. The company's yearly revenue for 2021 was $10.8M, representing an increase of 7.38% compared to 2020. CATX's yearly revenue for 2020 was $10.05M, representing an increase of 3.85% compared to 2019.
What is Perspective Therapeutics’s quarterly revenue?
Perspective Therapeutics's quarterly revenue for Q1 2023 was $1.91M, a 27.27% increase from the previous quarter (Q4 2022), and a 11.18% increase year-over-year (Q1 2022). The company's quarterly revenue for Q4 2022 was $1.5M, a -18.03% decrease from the previous quarter (Q3 2023), and a -40.12% decrease year-over-year (Q4 2021). CATX's quarterly revenue for Q3 2023 was $1.83M, a -0.27% decrease from the previous quarter (Q2 2023), and a -37.11% decrease year-over-year (Q3 2021).
What is Perspective Therapeutics’s revenue growth rate?
Perspective Therapeutics's revenue growth rate for the last 3 years (2020-2022) was -29.33%, and for the last 5 years (2018-2022) was -2.87%.